FGFR4 and TGF-β1 Expression in Hepatocellular Carcinoma: Correlation with Clinicopathological Features and Prognosis
被引:30
作者:
论文数: 引用数:
h-index:
机构:
Chen, Zhixin
[1
]
Xie, Bao
论文数: 0引用数: 0
h-index: 0
机构:
Wenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R China
Wenzhou Med Univ, Affiliated Hosp 2, Dept Pathol, Wenzhou, Zhejiang, Peoples R ChinaWenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R China
Xie, Bao
[1
,2
]
Zhu, Qinhua
论文数: 0引用数: 0
h-index: 0
机构:
Wenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R ChinaWenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R China
Zhu, Qinhua
[1
]
Xia, Qinghai
论文数: 0引用数: 0
h-index: 0
机构:
Wenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R ChinaWenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R China
Xia, Qinghai
[1
]
Jiang, Songmin
论文数: 0引用数: 0
h-index: 0
机构:
Wenzhou Ruian Peoples Hosp, Dept Pharm, Wenzhou, Zhejiang, Peoples R ChinaWenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R China
Jiang, Songmin
[3
]
Cao, Ruoyu
论文数: 0引用数: 0
h-index: 0
机构:
Cangzhou Cent Hosp, Dept Pediat, Cangzhou, Hebei, Peoples R ChinaWenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R China
Cao, Ruoyu
[4
]
论文数: 引用数:
h-index:
机构:
Shi, Lihua
[1
]
论文数: 引用数:
h-index:
机构:
Qi, Dansi
[2
]
论文数: 引用数:
h-index:
机构:
Li, Xiaokun
[1
]
论文数: 引用数:
h-index:
机构:
Cai, Lin
[1
]
机构:
[1] Wenzhou Med Univ, Sch Pharm, Dept Biopharmaceut, Wenzhou, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 2, Dept Pathol, Wenzhou, Zhejiang, Peoples R China
[3] Wenzhou Ruian Peoples Hosp, Dept Pharm, Wenzhou, Zhejiang, Peoples R China
[4] Cangzhou Cent Hosp, Dept Pediat, Cangzhou, Hebei, Peoples R China
Objective: To investigate the expression and correlation of transforming growth factor-beta 1 (TGF-beta 1) and fibroblast growth factor receptor 4 (FGFR4) in human hepatocellular carcinoma (HCC) and the relationship with clinicopathological features and prognosis. Materials and methods: The expression of TGF-beta 1 and FGFR4 in 126 HCC samples was detected immunohistochemically. Combined with clinical postoperative follow-up data, the expression of TGF-beta 1 and FGFR4 in HCC and the relationship with the prognosis of patients were analyzed by statistically. Results: The positive expression rate of TGF-beta 1 was 84.1% (106/126) in tumors, and that in peritumoral liver tissues was 64.3% (81/126); the positive expression rate of FGFR4 in tumors was 74.6% (94/126) and that in peritumoral liver tissues was 57.1% (72/126). The expression of TGF-beta 1 and FGFR4 in the carcinoma tissues was significantly higher than that in peritumoral liver tissues (p < 0.05). Intratumoral TGF-beta 1 and FGFR4 expression was associated with TNM stage (p < 0.05). TGF-beta 1 and FGFR4 expression levels didn't significantly correlate with other clinicopathological parameters, including age, sex, tumor size, serum AFP level, tumor differentiation, lymph node metastasis, etc. (p > 0.05). TGF-beta 1 expression was positively correlated with FGFR4 expression (r = 0.595, p < 0.05). Patients with positive FGFR4 or TGF-beta 1 expression had shorter overall survival compared with negative expression (p < 0.05). Conclusions: The expression of TGF-beta 1 and FGFR4 could make synergy on the occurrence and progression of HCC, and may be used as prognosis indicators for HCC patients.
机构:
Tokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, JapanTokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, Japan
机构:
Tokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, JapanTokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, Japan